Close Menu

RNAi

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week released data from an ongoing Phase II open-label extension study of its TTR-mediated amyloidosis therapy patisiran, which showed that the drug treatment was associated with a stabilization of neurological impairment progression in patients

NEW YORK (GenomeWeb) – Just days after presenting Phase II data on its lead hepatitis B drug candidate that failed to meet Wall Street expectations and sent its stock into a tailspin, Arrowhead Research has been sued in two class action lawsuits alleging that the company misled investors as to wh

NEW YORK (GenomeWeb) – While RNAi-based screens are routinely used to gain insights into biological pathways or to uncover novel therapeutic targets, a Salt Lake City-based startup is hoping that the technology can help find new uses for existing small-molecule drugs, particularly in the area of

NEW YORK (GenomeWeb) – RNAi startup Arcturus Therapeutics this week released new preclinical data on its lead transthyretin-mediated amyloidosis (ATTR) candidate LUNAR-101, showing that a single dose of the drug could cut levels of its target by more than 90 percent in non-human primates (NHPs) f

NEW YORK (GenomeWeb) – Japan's Nitto Denko announced this month that it has initiated a Phase Ib study of its siRNA-based fibrosis treatment ND-L02-s0201, just months after the drug successfully completed a Phase Ia safety study in healthy volunteers.

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week released new preclinical data showing that a next-generation version of its GalNAc conjugates has the potential to deliver siRNAs against liver targets when administered via inhalation.

Title: RNA Interference-mediating Small RNA Molecules
Patent Number: 8,853,384
Filed: Dec. 2, 2009

NEW YORK (GenomeWeb) — Biocept and Rosetta Genomics said today that they will collaborate in the area of cancer diagnostics.

NEW YORK (GenomeWeb) – Although Alnylam Pharmaceuticals has focused on rare, genetically defined diseases in recent years, the company sees opportunities to someday move back into the broader indications that once populated its research and development initiatives, a top company official said las

NEW YORK (GenomeWeb) – Shares of Arrowhead Research tumbled this week after the release of data from an ongoing Phase IIa trial of its siRNA-based hepatitis B drug ARC-520 showed unexpectedly modest reductions in HBV surface antigen (s-antigen), a key indicator of active infection.

Pages

The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.

The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.

Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.

In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.